The US Food and Drug Administration has clarified what it expects to see in drug master file (DMF) completeness assessments for active pharmaceutical ingredients (APIs)1.
FDA's expectations for completeness assessments were outlined in final guidance issued in February 2016. The pharmaceutical industry had complained that the draft guidance on the matter that was issued in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?